NL-OMON22602
Not yet recruiting
Not Applicable
A phase I/II trial towards the safety and efficacy of preemptive vaccination with PD-L silenced, minor histocompatibility antigen UTA2-1 peptide-loaded Dendritic Cells after Allogeneic Stem Cell Transplantation
VU University Medical Center0 sites17 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- VU University Medical Center
- Enrollment
- 17
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients with Multiple Myeloma (MM) or Chronic Lymphocytic Leukemia (CLL) or non hodgkin lymphoma (any grade) or acute myeloid leukemia (AML)
- •2\. Recipient and donor have a mismatch in UTA2\-1 mHag in the Graft versus Tumor (GvT) direction (recipient UTA2\-1 positive, donor UTA2\-1 negative).
- •4\. Recipient and donor are positive for HLA\-A\*0201
- •5\. Age 18\-75 years
- •6\. Absence of acute GvHD \> grade 2 or extensive chronic GvHD
- •7\. No treatment with immunosuppressive drugs such as prednisone, cyclosporine A and MMF at least 4 weeks prior to planned vaccination date.
- •8\. WHO performance 0\-2
- •9\. Absence of severe cardiac hepatic, renal, or metabolic disease
- •10\. Written informed consent
Exclusion Criteria
- •1\. WHO performance 3\-4
- •2\. Presence of severe cardiac hepatic, renal, metabolic disease
- •3\. Rapidly progressive disease,
- •4\. Life expectancy \< 3 months
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Tumor Antigen loaded Dendritic Cell Vaccination for hematological malignancies after allogeneic transplantatioMultiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Non hodgkin lymphoma (any grade), Acute myeloid leukemia (AML)MedDRA version: 20.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10025311 Term: Lymphoma (non-Hodgkin's) System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10009310 Term: CLL System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10001941 Term: AML System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-002752-33-NLVU University Medical Center12
Not yet recruiting
Not Applicable
A phase I/II trial towards the safety and efficacy of preemptive vaccination with PD-L silenced, minor histocompatibility antigen UTA2-1 peptide-loaded Dendritic Cells after Allogeneic Stem Cell TransplantatioNL-OMON45903Vrije Universiteit Medisch Centrum17
Active, not recruiting
Phase 1
The purpose of this study is to evaluate the safety and efficacy of the combination of two products Pexa-Vec and nivolumab for the treatment of liver cancerHepatocellular carcinomaMedDRA version: 21.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-000085-32-ITTRANSGENE SA55
Completed
Phase 1
A clinical trial to study safety and effects of P276-00 in combination with Gemcitabine in treatment of pancreatic cancer .CTRI/2009/091/000214Piramal Life Sciences Limited23
Active, not recruiting
Phase 1
Evaluation of safety and efficacy of DCVAC/LuCa (immunotherapy of lung cancer) in patients with metastatic lung cancerStage IV Non-Small Cell Lung CancerMedDRA version: 20.1Level: PTClassification code 10025070Term: Lung carcinoma cell type unspecified stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2014-003084-37-CZSOTIO a.s.98